GW Pharmaceuticals PLC- (NASDAQ:GWPH) Shares Purchased by GW&K Investment Management LLC

GW&K Investment Management LLC lifted its position in GW Pharmaceuticals PLC- (NASDAQ:GWPH) by 43.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 37,745 shares of the biopharmaceutical company’s stock after purchasing an additional 11,474 shares during the quarter. GW&K Investment Management LLC’s holdings in GW Pharmaceuticals PLC- were worth $4,342,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Envestnet Asset Management Inc. lifted its position in GW Pharmaceuticals PLC- by 4.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 2,014 shares of the biopharmaceutical company’s stock worth $347,000 after acquiring an additional 92 shares during the period. Steward Partners Investment Advisory LLC lifted its position in GW Pharmaceuticals PLC- by 9.4% during the 3rd quarter. Steward Partners Investment Advisory LLC now owns 1,163 shares of the biopharmaceutical company’s stock worth $133,000 after acquiring an additional 100 shares during the period. Close Asset Management Ltd lifted its position in GW Pharmaceuticals PLC- by 13.5% during the 2nd quarter. Close Asset Management Ltd now owns 876 shares of the biopharmaceutical company’s stock worth $151,000 after acquiring an additional 104 shares during the period. Aperio Group LLC lifted its position in GW Pharmaceuticals PLC- by 4.0% during the 2nd quarter. Aperio Group LLC now owns 2,763 shares of the biopharmaceutical company’s stock worth $476,000 after acquiring an additional 106 shares during the period. Finally, D.A. Davidson & CO. lifted its position in GW Pharmaceuticals PLC- by 3.3% during the 2nd quarter. D.A. Davidson & CO. now owns 3,611 shares of the biopharmaceutical company’s stock worth $623,000 after acquiring an additional 117 shares during the period. 83.39% of the stock is owned by hedge funds and other institutional investors.

In related news, insider Douglas B. Snyder sold 5,424 shares of the firm’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $13.04, for a total value of $70,728.96. Following the completion of the transaction, the insider now directly owns 73,740 shares of the company’s stock, valued at approximately $961,569.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 3.60% of the company’s stock.

Several analysts have recently commented on GWPH shares. BidaskClub cut GW Pharmaceuticals PLC- from a “hold” rating to a “sell” rating in a report on Saturday. Bank of America reissued a “buy” rating and issued a $218.00 price target on shares of GW Pharmaceuticals PLC- in a report on Wednesday, September 25th. Zacks Investment Research raised GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating and set a $122.00 price target for the company in a report on Saturday. Morgan Stanley raised their price target on GW Pharmaceuticals PLC- to $238.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Finally, Needham & Company LLC started coverage on GW Pharmaceuticals PLC- in a report on Monday, October 21st. They issued a “buy” rating and a $200.00 price target for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $199.18.

Shares of GWPH traded up $3.26 during mid-day trading on Wednesday, hitting $112.66. The company’s stock had a trading volume of 13,388 shares, compared to its average volume of 513,140. The company has a current ratio of 7.33, a quick ratio of 6.60 and a debt-to-equity ratio of 0.03. The firm has a 50-day simple moving average of $121.50 and a 200 day simple moving average of $153.45. The firm has a market capitalization of $3.38 billion, a P/E ratio of -10.66 and a beta of 2.28. GW Pharmaceuticals PLC- has a 1-year low of $90.14 and a 1-year high of $196.00.

GW Pharmaceuticals PLC- Profile

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Recommended Story: What are benefits of a growth and income fund?

Want to see what other hedge funds are holding GWPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GW Pharmaceuticals PLC- (NASDAQ:GWPH).

Institutional Ownership by Quarter for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.